BioSpace News Archive

With studies suggesting primary hepatocytes can quickly lose many of their in vivo functions when cultured as a monolayer.

The conference, which is being held February 5-9, 2018 in San Diego, CA, presents the latest information from basic science, translational research and clinical trials for lysosomal diseases.

The conference, which is being held February 5-9, 2018 in San Diego, CA, presents the latest information from basic science, translational research and clinical trials for lysosomal diseases.

The six posters evaluate the safety of Cladribine Tablets and its impact on the immune system via post hoc analyses of the CLARITY, CLARITY Extension, and ORACLE-MS trials, as well as the PREMIERE registry study.

A002 previously received orphan drug designation from the FDA and the European Medicines Agency for the treatment of ACHM in 2016.

Neogen that it has released BetaStar Advanced -- the easiest method to test for antibiotics in milk.

icralyne Inc., a leading manufacturer of biomedical MicroElectroMechanical Systems (MEMS) and sensors announces the launch of the MicraFluidics™ technology - a line of standardized microfluidic process technologies to support high demand from the biomedical and life-sciences industry for rapid design and deployment of integrated microfluidic-based products.

Under the terms of the agreement, Elekta will now offer EQUICARE CS™ and Equicare’s Active Patient Portal to current and future users of Elekta’s MOSAIQ® Oncology Electronic Health Record (EHR). EQUICARE CS and the Active Patient Portal complement MOSAIQ, facilitating communication between patients and clinicians with no geographic restrictions.

Mallinckrodt today announced that Mark Casey has been appointed General Counsel, effective immediately.

OncoSec Medical announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price of $1.50 per share, with expected gross proceeds of approximately $20 million, before deducting underwriting discounts and commissions and estimated offering expenses paid by OncoSec.